Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

[1]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[2]  D. Maric,et al.  Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide–HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections , 2003, Nature Medicine.

[3]  Mark M. Davis,et al.  Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. , 2003, The Journal of clinical investigation.

[4]  J. Berzofsky,et al.  Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC , 2003, The Journal of Immunology.

[5]  T. Whiteside,et al.  Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  T. Mosmann,et al.  Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing , 2003, Nature Medicine.

[7]  V. Sondak,et al.  Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma , 2003, Cancer.

[8]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Romero,et al.  Dissecting TCR‐MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes , 2002, European journal of immunology.

[10]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[11]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[12]  M. Alexander-Miller,et al.  Optimal Colocalization of TCR and CD8 as a Novel Mechanism for the Control of Functional Avidity1 , 2002, The Journal of Immunology.

[13]  F. Mami-Chouaib,et al.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[15]  Austin L. Hughes,et al.  Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection , 2002, Nature Medicine.

[16]  D. Speiser,et al.  Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR1 , 2002, The Journal of Immunology.

[17]  S. Groshen,et al.  Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Whitton,et al.  Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR , 2001, Nature Immunology.

[19]  D. Margulies.  TCR avidity: it's not how strong you make it, it's how you make it strong , 2001, Nature Immunology.

[20]  J. Berzofsky,et al.  Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. , 2001, International immunology.

[21]  G. Freeman,et al.  Examination of CD8+ T Cell Function in Humans Using MHC Class I Tetramers: Similar Cytotoxicity but Variable Proliferation and Cytokine Production Among Different Clonal CD8+ T Cells Specific to a Single Viral Epitope , 2000, The Journal of Immunology.

[22]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[23]  M. Davis,et al.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. , 1999, Journal of immunology.

[24]  M. Bachmann,et al.  Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection , 1999, European journal of immunology.

[25]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[26]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.